High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort

Infection

Volumn 30, Issue 6, 2002, Pages 356-359

  Horban, A ^a   Stanczak, J J ^a   Bakowska E ^a   Tobolewska, E J ^a   Przybylska Stengiel, K J ^a   Stanczak, G P ^a   Burkacka, E ^a  

^a SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; GENE MUTATION; GENETIC ANALYSIS; GENETIC CODE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYBRIDIZATION; MAJOR CLINICAL STUDY; MUTANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS STRAIN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LAMIVUDINE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; ZIDOVUDINE;

EID: 0036452857     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-002-3055-4     Document Type: Article

References (20)

1. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vezinet F: Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000; 283: 205-211.
2. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44: 902-908.
3. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, Richman DD, Morris D, Hubbell E, Chee M, Gingeras TR: Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996; 2: 753-759.
4. Stuyver L,Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C, Rimland D, Schinazi RF, Rossau R: Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother 1997: 41: 284-291.
5. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P: Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 1999; 353: 2195-2199.
6. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC: A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000;14: 83-93.
7. INNO-LiPA HIV-1 RT Protocol. INNOGENETICS N.V. 1999
8. INNO-LiPA HIV-Resistance. Annex 7. INNOGENETICS N.V. 2001
9. GuideLine Rules 4.0 and 5.0. Visible Genetics Inc. 2001-2002
10. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R, De Luca A: Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA). AIDS 2002; 16: 369-379.
11. Falloon J, Ait-Khaled M, Thomas DA, Brosgart CL, Eron Jr JJ, Feinberg J, Flanigan TP, Hammer SM, Kraus PW, Murphy R, Torres R, Masur H, CNA2007 Study Team: HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS 2002; 16: 387-396.
12. Horban A, Ba̧kowska E, Pulik P, Ignatowska A, Tobolewska E, Stanczak JJ: Genotypic analysis of HIV strains resistant to NRTIs in naive patients. Antiviral Ther 2001; 6: 66.
13. Coakley E, Gillis J, Hammer S: Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with ddI and d4T in combination. AIDS 2000; 14: 9-16.
14. de Mendoza C, Soriano V, Briones C, Gallego O, Barreiro P, Alvarez A, Gonzalez-Lahoz J.: Emergence of zidovudine resistance in HIV-infected patients receiving stavudine. J Acquir Immune Defic Syndr 2000; 23: 279-281.
15. Wegner SA, Brodine SK, Mascola JR, Tasker SA, Shaffer RA, Starkey MJ, Barile A, Martin GJ, Aronson N, Emmons WW, Stephan K, Bloor S, Vingerhoets J, Hertogs K, Larder B: Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS 2000; 14: 1009-1015.
16. Little SJ: Transmission and prevalence of HIV resistance among treatment-naive subjects. Antiviral Ther 2000; 5: 33-40.
17. Yerly S, Vora S, Rizzardi P, Chave JP, Vernazza PL, Flepp M, Telenti A, Battegay M, Veuthey AL, Bru JP, Rickenbach M, Hirschel B, Perrin L, Swiss HIV Cohort Study: Acute HIV infection: Impact on the spread of HIV and transmission of drug resistance. AIDS 2001; 15: 2287-2292.
18. Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N, Markowitz M: HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282: 1135-1141.
19. Hanna GJ, D'Aquila RT: Antiretroviral drug resistance in HIV-1. Curr Infect Dis Rep 1999; 1: 289-297.
20. Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM: Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: Genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS Clinical Trials Group Protocol 315. J Infect Dis 2000; 181: 491-477.